Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes

Keyphrases

• Graft-versus-host Disease (GvHD) 100%
• Clinical Outcomes 100%
• Post-transplantation Cyclophosphamide (PTCy) 100%
• Tacrolimus 8%
• Adult Patients 8%
• Treatment Response 8%
• Mycophenolate Mofetil 8%
• Hematopoietic Cell Transplantation 8%
• Corticosteroids 8%
• Low Incidence 8%
• Systemic Corticosteroids 8%
• University of Minnesota 4%
• Treatment-resistant 4%
• Risk Factors 4%
• Pediatric Patients 4%
• High Risk 4%
• Bone Marrow 4%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 4%
• Systemic Therapy 4%
• Cause of Death 4%
• Allograft 4%
• Standard of Care 4%
• Living Donor 4%
• Prophylactic Treatment 4%
• Disease Prevention 4%
• Reduced-intensity Conditioning 4%
• Disease Treatment 4%
• Poor Survival 4%
• Non-relapse Mortality 4%
• Overall Survival 4%
• Myeloablative 4%
• Single Institution 4%
• Group of Twenty 4%
• Unrelated Donor 4%
• Time to Onset 4%
• Median Time 4%
• Systemic Treatment 4%
• Graft Source 4%
• Response Group 4%
• GVHD Treatment 4%
• Peripheral Blood Stem Cell Graft 4%
• Malignant Disorders 4%
• Following Response 4%
• Response Categories 4%

Immunology and Microbiology

• Graft-Versus-Host Disease 100%
• Acute Graft Versus Host Disease 100%
• Cyclophosphamide 100%
• Cell Transplantation 13%
• Hematopoietic Cell 13%
• Mycophenolic Acid 9%
• Tacrolimus 9%
• Peripheral Blood Stem Cell 4%
• Conditioning 4%
• Overall Survival 4%
• Allotransplantation 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Graft Versus Host Reaction 100%
• Acute Graft Versus Host Disease 100%
• Cyclophosphamide 100%
• Corticosteroid 9%
• Tacrolimus 9%
• Mycophenolic Acid 9%
• Cohort Study 4%
• Systemic Treatment 4%
• Overall Survival 4%
• Disease 4%
• Combination Therapy 4%